Precision BioSciences Bolsters Hepatitis Scientific Advisory Board with Mark Sulkowski and Jordan Feld as PBGENE-HBV Program Advances
DURHAM, N.C. - Precision BioSciences, a leading gene editing company specializing in advanced in vivo gene editing therapies, has recently announced the appointment of two renowned clinical investigators, Mark Sulkowski, M.D. and Jordan Feld, M.D. M.P.H. to its Hepatitis Scientific Advisory Board (SAB). The addition of these world-class experts comes as the company’s PBGENE-HBV program approaches clinical readiness, marking a significant milestone in Precision BioSciences’ aim to combat hepatitis.
Precision BioSciences is known for its cutting-edge ARCUS platform, a proprietary gene editing technology that allows for precise and sophisticated gene edits, including gene elimination, insertion, and excision. With a focus on developing innovative therapies for various genetic disorders, Precision BioSciences is now looking to tackle hepatitis, a global health challenge affecting millions of individuals.
The appointment of Dr. Sulkowski and Dr. Feld to the SAB brings unparalleled expertise to Precision BioSciences’ already impressive team. Dr. Sulkowski, a highly-regarded figure in the field of hepatology, is a renowned expert in viral hepatitis. As the Medical Director of the Viral Hepatitis Center at Johns Hopkins University, he has been instrumental in advancing the understanding and treatment of hepatitis. His contributions to the field include major breakthroughs in the development of direct-acting antiviral (DAA) therapies for hepatitis C.
Dr. Feld, a clinician-scientist based at the University of Toronto, is recognized for his significant contributions to the study and treatment of viral hepatitis, particularly hepatitis B. Beyond his expertise in clinical research, he has been actively involved in leading large multi-center clinical trials that have had a profound impact on the field.
The inclusion of Dr. Sulkowski and Dr. Feld in Precision BioSciences’ SAB demonstrates the company’s commitment to leveraging the expertise of world-class clinical investigators to advance their research and development efforts. Together with the inaugural member of the SAB, Raymond Schinazi, Ph.D. DSc, this prominent group of experts will provide invaluable guidance and insights as the PBGENE-HBV program moves closer to clinical trials.
Precision BioSciences’ PBGENE-HBV program aims to develop gene editing therapies specifically designed to eliminate or modify the hepatitis B virus (HBV) in infected individuals. Currently, there are limited treatment options available for HBV, and Precision BioSciences recognizes the urgent need for more effective therapies. By leveraging their expertise in gene editing and harnessing the power of ARCUS, Precision BioSciences hopes to revolutionize the treatment landscape for HBV.
The addition of Dr. Sulkowski and Dr. Feld to the Hepatitis Scientific Advisory Board helps to bolster Precision BioSciences’ strategic approach in combating hepatitis. The expertise and knowledge brought by these experts will undoubtedly provide a strong foundation for the success of the PBGENE-HBV program.
In conclusion, Precision BioSciences’ announcement of the inclusion of Mark Sulkowski, M.D. and Jordan Feld, M.D. M.P.H. to its Hepatitis Scientific Advisory Board signals a significant step forward in the company’s research and development efforts. As the PBGENE-HBV program nears clinical readiness, the addition of these world-class clinical investigators will undoubtedly enhance Precision BioSciences’ ability to tackle hepatitis effectively. By harnessing the power of ARCUS, Precision BioSciences aims to bring about a new era in hepatitis treatment and improve the lives of millions affected by this global health challenge.
Comments